

United States Patent and Trademark Office

TAT

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/525,363	09/06/2005	Kathryn Elizabeth Lawlor	18688	5197
272 SCHIIV SC	7590 08/22/2007 DTT, MURPHY & PRESSI	GD DC	EXAMINER WOODWARD, CHERIE MICHELLE	
400 GARDEN	CITY PLAZA	ck, i.c.		
SUITE 300 GARDEN CIT	Y. NY 11530		ART UNIT	PAPER NUMBER
	-,		1647	
			MAIL DATE	DELIVERY MODE
			08/22/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/525,363	LAWLOR ET AL.	LAWLOR ET AL.	
Office Action Summary	Examiner	Art Unit		
	Cherie M. Woodward	1647		
The MAILING DATE of this communication ariod for Reply	appears on the cover sheet wit	h the correspondence address	S	
A SHORTENED STATUTORY PERIOD FOR REL WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the may be available term adjustment. See 37 CFR 1.704(b).	B DATE OF THIS COMMUNIC R 1.136(a). In no event, however, may a re- riod will apply and will expire SIX (6) MONT atute, cause the application to become ABA	ATION. ply be timely filed 'HS from the mailing date of this communation ANDONED (35 U.S.C. § 133).		
atus				
Responsive to communication(s) filed on 23 This action is FINAL . 2b) ☑ T Since this application is in condition for allow closed in accordance with the practice under	his action is non-final. wance except for formal matte	ers, prosecution as to the mer	rits is	
sposition of Claims				
4)	drawn from consideration.			
pplication Papers				
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the cort 11) The oath or declaration is objected to by the	accepted or b) objected to be the drawing(s) be held in abeyand rection is required if the drawing(ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.		
iority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the papplication from the International Bur * See the attached detailed Office action for a	ents have been received. ents have been received in Appriority documents have been reau (PCT Rule 17.2(a)).	oplication No received in this National Stag	e	
achment(s) Notice of References Cited (PTO-892)	4) 🔲 Interview Si	ummary (PTO-413)		

Page 2

Application/Control Number: 10/525,363

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-5, 8, 11-14, and 18, drawn to a method of treating arthritis.

Group II, claims 22, and 29-31, as they drawn to a composition comprising an antibody.

Group III, claims 22 and 32, as they are drawn to a composition comprising a soluble G-CSFR.

Group IV, claims 22 and 36, as they are drawn to a composition comprising a polynucleotide.

- 2. The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: claim 1 is anticipated by US Patent 5,449,515 (12 September 1995). The '515 patent teaches the administration of IL-4, which decreases the level of expression of G-CSF in a method of treating arthritis (column 5, lines 10-15; claims 1, 11, and 12). The '515 patent teaches all of the limitations of claim 1. As such, the remaining claims lack the same or corresponding special technical feature and restriction is required. See 37 CFR 1.475 and MPEP 1850.
- 3. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

Application/Control Number: 10/525,363

Art Unit: 1647

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 10/525,363

Art Unit: 1647

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cherie M. Woodward whose telephone number is (571) 272-3329. The examiner can normally be reached on Monday - Friday 9:00am-5:30pm (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CMW AU 1647 /Manjunath Rao/ Supervisory Patent Examiner Art Unit 1647